Yang Kun, Zhang Ying, Chou Robert, Yeung Lai, Letarte Simon, Yang Rong-Sheng, Li Xuanwen, Beaumont Maribel, Gunawan Rico, Richardson Douglas, Dellatore Shara, Woolf Eric, Xu Yang
Regulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Biologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
ACS Pharmacol Transl Sci. 2020 Oct 28;3(6):1310-1317. doi: 10.1021/acsptsci.0c00135. eCollection 2020 Dec 11.
The robustness of good laboratory practice and clinical data is reliant upon a clear understanding of the bioanalytical assays. One of the most important components of ligand-binding based assays is critical reagents used to directly or indirectly measure biologic markers or signals. High quality, reproducible, sustainable critical reagents through the development lifecycle could avoid unnecessary rework, multiple validations, cross-validations, and ensure consistency of the data. Numerous analytical methods (UPLC-size exclusion chromatography, cation exchange chromatography, biacore/octet, and high-resolution mass spectrometry) have been evaluated by using current critical reagents. A comprehensive analytical toolbox of biochemical and biophysical methods has been employed to evaluate the quality of critical reagents and explore potential issues if there are any. Moving forward, this "tiered approach" of critical reagents characterization will be used not only to establish critical quality attributes for new reagents but also to evaluate stability in support of reagents recertification.
良好实验室规范和临床数据的稳健性依赖于对生物分析测定的清晰理解。基于配体结合的测定中最重要的组成部分之一是用于直接或间接测量生物标志物或信号的关键试剂。在整个开发生命周期中，高质量、可重现、可持续的关键试剂可以避免不必要的返工、多次验证、交叉验证，并确保数据的一致性。使用当前的关键试剂对众多分析方法（超高效液相色谱-尺寸排阻色谱、阳离子交换色谱、生物传感器/八通道分子相互作用分析仪和高分辨率质谱）进行了评估。已采用一套综合的生化和生物物理方法分析工具箱来评估关键试剂的质量，并探索是否存在潜在问题。展望未来，这种关键试剂表征的“分层方法”不仅将用于确定新试剂的关键质量属性，还将用于评估稳定性以支持试剂重新认证。
